May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Mar 18, 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Dec 13, 2018
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Dec 12, 2018
Nationwide Program Brings Hope Home to Lung Cancer Patients During the Holidays
Oct 11, 2018
FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Sep 12, 2018
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Jun 23, 2018
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
Jun 19, 2018
Medisafe Announces Partnership with Boehringer Ingelheim to Support U.S. Pradaxa Patients
Mar 28, 2018
Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease - IPF
Mar 09, 2018
Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
Feb 16, 2018
New initiative raises awareness of scleroderma through real-life stories of those living with the rare disease
Feb 09, 2018
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
Dec 20, 2017
Knowledge Of Biosimilars: Survey Of 100+ U.S. Rheumatologists Shows Familiarity But Need For Further Education
Dec 07, 2017
Holiday Program Brings Hope Home to Lung Cancer Patients
Nov 09, 2017
Diversity in clinical trials critical to refining medicines and therapies
Nov 06, 2017
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Oct 30, 2017
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Sep 19, 2017
New Documentary Film Shines Light on Physical and Emotional Impact of COPD
Aug 29, 2017
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo(TM) (adalimumab-adbm), a biosimilar to Humira®, for the treatment of multiple chronic inflammatory diseases
Jul 27, 2017
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira®